Ignite Creation Date:
2024-05-05 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00111540
Status:
COMPLETED
Last Update Posted:
2015-02-23
First Post:
2005-05-23
Brief Title:
Study to Examine the Effect on Glucose Control and SafetyTolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
An Open Label Study to Examine the Long Term Effect on Glucose Control HbA1c and Safety and Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2015-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This open label study is designed to assess long term glucose control as measured by hemoglobin A1c HbA1c and to evaluate long term safety and tolerability in subjects with type 2 diabetes mellitus who receive subcutaneously injected exenatide administered twice a day
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None